The FDA just published its first-ever standalone guidance on how to respond to a Form 483.

Until now, the conventions around what makes a good response have lived mostly in tribal knowledge: what experienced consultants knew, what quality leaders picked up over years of interacting with investigators, and what district offices expected but never formally wrote down.

Now it's in writing. And the bar is higher than a lot of companies realize.

We broke down the full guidance — what the FDA actually expects in terms of response format, investigation rigor, CAPA planning, management accountability, and interim reporting — along with where companies most commonly fall short and what to do about it.